<DOC>
	<DOCNO>NCT02890368</DOCNO>
	<brief_summary>This multicenter , open-label , phase 1 study do test intratumoral injection TTI-621 subject relapse refractory percutaneously accessible solid tumor mycosis fungoides . The study perform two different part . Part 1 Dose Escalation phase Part 2 Dose Expansion phase . The purpose study characterize safety profile TTI-621 determine optimal dose delivery schedule TTI-621 .</brief_summary>
	<brief_title>Trial Intratumoral Injections TTI-621 Subjects With Relapsed Refractory Solid Tumors Mycosis Fungoides</brief_title>
	<detailed_description>This multicenter , open-label , phase 1 study do test intratumoral injection TTI-621 patient relapse refractory percutaneously accessible solid tumor mycosis fungoides . The study perform two different part : Dose Escalation Dose Expansion . During escalation part study , TTI-621 study 3 different dose level different dose frequency characterize safety , tolerability , pharmacokinetics , determine maximum tolerate dose ( MTD ) . During expansion part study , TTI-621 study expand group patient dose frequency acceptable level side effect escalation part study . The expansion phase define safety characterize efficacy . The purpose study characterize safety profile TTI-621 determine optimal dose delivery schedule TTI-621 .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Merkel Cell</mesh_term>
	<criteria>Histologically cytologically document , injectable cancer lesion ( limited solid tumor mycosis fungoides ) Adequate renal function Adequate coagulation function Adequate hepatic function Disease progress standard therapy therapy option available Central nervous system involvement Significant cardiovascular disease Active autoimmune disease Active hepatitis B C history HIV infection Uncontrolled infection History hemolytic anemia bleed diathesis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>CD47</keyword>
	<keyword>SIRPa</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Checkpoint inhibitor</keyword>
</DOC>